Connect with us

coronavirus

EU begins real-time review of Sanofi-GSK COVID-19 vaccine

SHARE:

Published

5 years ago

on

We use your sign-up to provide content in ways you've consented to and to improve our understanding of you. You can unsubscribe at any time.

A Sanofi logo is seen during the company's annual results news conference in Paris, France, February 6, 2020. REUTERS/Benoit Tessier
A GlaxoSmithKline (GSK) logo is seen at the GSK research centre in Stevenage, Britain November 26, 2019. REUTERS/Peter Nicholls

Europe's drug regulator said on Tuesday (20 July) it had started a real-time review of the COVID-19 vaccine developed by French drugmaker Sanofi (SASY.PA) and Britain's GlaxoSmithKline (GSK.L), the fifth shot currently under such a review, write Pushkala Aripaka in Bengaluru and Matthias Blamont in Paris, Reuters.

The decision to start the "rolling review" of the vaccine, Vidprevtyn, was based on preliminary results from lab studies and early stage clinical trials in adults, the European Medicines Agency (EMA) said.

Late-stage global trials for the protein-based coronavirus vaccine candidate began in May.

Sanofi and GSK hope to get approvals by the end of 2021 after early-stage results showed the vaccine produces a robust immune response. read more

"EMA will assess the compliance of Vidprevtyn with the usual EU standards for effectiveness, safety and quality," the regulator said, without giving details on data it had received so far and an expected timeline for approval.

EMA's rolling reviews are aimed at speeding up the approval process by allowing researchers to submit findings in real time before final trial data is available.

Sanofi said other rolling reviews of its vaccine were also about to start in Britain, Canada and Singapore, as well as with the World Health Organization.

Vidprevtyn uses the same technology as one of Sanofi's seasonal influenza vaccines. It will be coupled with an adjuvant, a substance that acts as a booster to the shot, made by GSK.

Other COVID-19 vaccine candidates in EU's rolling review are those from CureVac (5CV.DE), Novavax (NVAX.O), Sinovac (SVA.O) and Russia's Sputnik V.

Share this article:

Share this:
Related Topics:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Advertisement

Trending